$2.68
+25%Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. It provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia.
Last Annual Value
4.09B
3-Year CAGR
16%
5-Year CAGR
5%
10-Year CAGR
9%
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Owens & Minor, Inc. NYSE:OMI | 4.09B | -0.6% | 9.5% | 8.8% | |
![]() Outset Medical, Inc. NASDAQ:OM | 137.54M | -10.4% | 9.0% | N/A | |
![]() CVRx, Inc. NASDAQ:CVRX | 65.47M | 18.6% | 58.3% | N/A | |
![]() Allogene Therapeutics, Inc. NASDAQ:ALLO | 123.36M | -1.9% | -0.4% | N/A | |
![]() Definitive Healthcare Corp. NASDAQ:DH | 356.50M | -17.1% | -10.4% | N/A | |
![]() Humacyte, Inc. NASDAQ:HUMA | 113.26M | -0.4% | -7.2% | N/A | |
![]() Lyell Immunopharma, Inc. NASDAQ:LYEL | 91.85M | -1.1% | -14.2% | N/A | |
![]() NeuroPace, Inc. NASDAQ:NPCE | 86.53M | -0.2% | 7.6% | N/A | |
![]() Replimune Group, Inc. NASDAQ:REPL | 135.49M | 14.1% | 25.0% | N/A | |
![]() Semler Scientific, Inc. NASDAQ:SMLR | 9.08M | 13.1% | 12.1% | 4.2% | |
![]() Perspective Therapeutics, Inc. AMEX:CATX | 59.94M | 38.2% | 83.8% | 43.1% |
Continue your OMI research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.